GAURI R VARADHACHARY to Deoxycytidine
This is a "connection" page, showing publications GAURI R VARADHACHARY has written about Deoxycytidine.
Connection Strength
1.814
-
A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary. Int J Clin Oncol. 2013 Apr; 18(2):226-31.
Score: 0.276
-
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 2021 01; 22(1):118-131.
Score: 0.129
-
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2020 09 01; 155(9):832-839.
Score: 0.126
-
Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med. 2020 08; 9(15):5406-5415.
Score: 0.124
-
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jun 01; 5(6):824-830.
Score: 0.115
-
First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2019 Feb; 26(2):619-627.
Score: 0.110
-
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J Hematol Oncol. 2018 05 30; 11(1):71.
Score: 0.107
-
Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Phys Biol. 2014 Nov 26; 11(6):065002.
Score: 0.084
-
Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest. 2014 Apr; 124(4):1525-36.
Score: 0.080
-
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs. 2011 Aug; 29(4):694-9.
Score: 0.060
-
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008 Jul 20; 26(21):3487-95.
Score: 0.054
-
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008 Jul 20; 26(21):3496-502.
Score: 0.054
-
Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. Radiat Oncol. 2006 Oct 24; 1:41.
Score: 0.048
-
Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy. Semin Oncol. 2005 Dec; 32(6 Suppl 9):S40-2.
Score: 0.045
-
Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys. 2022 11 01; 114(3):444-453.
Score: 0.036
-
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med. 2021 08; 10(15):5041-5050.
Score: 0.033
-
Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX. Pancreas. 2019 07; 48(6):837-843.
Score: 0.029
-
Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma. Oncologist. 2019 06; 24(6):e384-e386.
Score: 0.028
-
Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056.
Score: 0.026
-
Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. Ann Surg Oncol. 2015 Jul; 22(7):2416-23.
Score: 0.021
-
Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014 Jan; 18(1):16-24; discussion 24-5.
Score: 0.020
-
A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol. 2013 Sep; 24(9):2349-53.
Score: 0.019
-
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs. 2013 Oct; 31(5):1375-83.
Score: 0.019
-
Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012 Jun; 19(6):2045-53.
Score: 0.017
-
Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg. 2012 Jan; 16(1):68-78; discussion 78-9.
Score: 0.017
-
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011 Aug 01; 29(22):3037-43.
Score: 0.017
-
Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1431-8.
Score: 0.016
-
The integration of chemoradiation in the care of patient with localized pancreatic cancer. Cancer Radiother. 2009 Apr; 13(2):123-43.
Score: 0.014
-
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009 Jun 01; 27(16):2598-603.
Score: 0.014
-
Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 2008 Oct 15; 113(8):2046-52.
Score: 0.014
-
Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. Int J Radiat Oncol Biol Phys. 2008 Mar 01; 70(3):735-43.
Score: 0.013
-
Future chemoradiation strategies in pancreatic cancer. Semin Oncol. 2007 Aug; 34(4):335-46.
Score: 0.013
-
Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007 Jul 01; 110(1):47-55.
Score: 0.013
-
Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer. 2006 Dec 01; 107(11):2589-96.
Score: 0.012
-
The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006 Apr; 20(2):365-82.
Score: 0.012